{"id":12029,"date":"2025-04-11T22:44:21","date_gmt":"2025-04-11T22:44:21","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/12029\/"},"modified":"2025-04-11T22:44:21","modified_gmt":"2025-04-11T22:44:21","slug":"genetic-screening-testing-for-preventive-health-market-top","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/12029\/","title":{"rendered":"Genetic Screening Testing for Preventive Health Market Top"},"content":{"rendered":"

\"Genetic<\/a><\/p>\n

Genetic Screening Testing for Preventive Health Market<\/p>\n

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global Genetic Screening Testing for Preventive Health Market – By Test Type (Carrier Screening Tests (Expanded Carrier Screening, Targeted Carrier Screening), Non-Invasive Prenatal Tests, Preimplantation Genetic Testing, And Newborn Screening), Technology (NGS, Microarray, PCR, FISH), Application (Oncology, Cardiovascular Diseases, Reproductive Health, Neurodegenerative Health, Rare Diseases), And End-User (Hospitals And Diagnostic Laboratories, Dtc Companies, Genetic Counselling Services), Trends, Industry Competition Analysis, Revenue And Forecast To 2034.”<\/p>\n

Genetic Screening Testing for Preventive Health Market is predicted to grow at a 11.8% CAGR during the forecast period for 2025-2034. <\/p>\n

Get Free Access to Demo Report, Excel Pivot and ToC: https:\/\/www.insightaceanalytic.com\/request-sample\/2956<\/p>\n

Genetic screening tests for preventative health are those that analyze an individual’s genetic makeup to foretell their susceptibility to specific diseases or conditions in the future. The objective of these tests is to detect genetic predispositions to specific diseases, including diabetes, cancer, heart disease, and other hereditary malady. The market for genetic screening testing for preventive health is influenced by a number of critical variables. The accuracy, affordability, and accessibility of these procedures have been enhanced by advancements in genetic testing technology, such as next-generation sequencing (NGS). The necessity has also been stimulated by the increasing cost of healthcare, the increased emphasis on prevention, and the increasing awareness of the benefits of early detection among consumers.<\/p>\n

List of Prominent Players in the Genetic Screening Testing for Preventive Health Market:

\n\u2022\tExact Science

\n\u2022\tLabcorp Genetics Inc.

\n\u2022\tDante Labs US

\n\u2022\tMyriad Genetics, Inc.

\n\u2022\tBlueprint Genetics

\n\u2022\tAmbry Genetics

\n\u2022\tRevvity

\n\u2022\tLaboratory Corporation of America Holdings

\n\u2022\tBGI Group

\n\u2022\tGenex Diagnostics Inc.

\n\u2022\tSonic Healthcare

\n\u2022\tFulgent Genetics<\/p>\n

Expert Knowledge, Just a Click Away: https:\/\/calendly.com\/insightaceanalytic\/30min?month=2025-04<\/p>\n

Market Dynamics:

\nDrivers-

\nTechnical developments, the rise of tailored treatment, and the development of preventive healthcare projects have been driving fast expansion of the market for genetic screening tests in preventive health from a variety of perspectives. Demand has been driven in part by rising healthcare costs, increased focus on prevention, and public awareness of the benefits of early discovery. Furthermore, growing availability of direct-to—consumer genetic testing lets consumers take initiative with their health. Among the market participants are healthcare providers, hospitals, diagnostic labs, wellness-oriented groups, and genetic testing companies. As more people search for tailored, data-driven healthcare solutions, it is expected that demand for genetic tests as a preventive strategy will grow.<\/p>\n

Challenges:

\nThe high expense of sophisticated genetic tests, which restrict accessibility, especially in low- and middle-income areas, is one of the factors impeding the expansion of genetic screening testing for the preventive health market. Many people face financial obstacles as a result of the variable insurance coverage for genetic screening. Furthermore, patients and regulatory agencies are calling for stronger data protection measures, which presents serious ethical and privacy issues with the use of genetic data. Lower adoption rates are also a result of the general public’s and even certain healthcare professionals’ lack of knowledge and comprehension of genetic screening.<\/p>\n

Regional Trends:

\nStrong healthcare infrastructure, growing consumer awareness, and technological innovations would help the North American Genetic Screening Testing for Preventive Health market to register a significant market share in terms of revenue. Particularly the United States is a prominent participant due of its well-established healthcare system, significant research on genetic testing, and growing focus on tailored therapy. Moreover, the advent of direct-to—consumer genetic testing firms like 23andMe has helped to increase market presence. Besides, Europe held a sizable portion of the market since countries like France, Germany, and the United Kingdom made large expenditures on preventative medicine. On the European market, demand is great for genetic tests for cancer, cardiovascular disease, and neurological conditions. Strong medical rules supporting genetic testing benefit the field.<\/p>\n

Unlock Your GTM Strategy: https:\/\/www.insightaceanalytic.com\/customisation\/2956<\/p>\n

Segmentation of Genetic Screening Testing for Preventive Health Market-

\nBy Test Type-

\n\u2022\tCarrier Screening Test

\no\tExpanded Carrier Screening

\no\tTargeted Carrier Screening

\n\u2022\tNon-Invasive Prenatal Test

\n\u2022\tPreimplantation Genetic Testing

\n\u2022\tNewborn Screening

\nBy Technology-

\n\u2022\tNGS

\n\u2022\tMicroarray

\n\u2022\tPCR

\n\u2022\tFISH

\n\u2022\tOthers

\nBy Application-

\n\u2022\tOncology

\n\u2022\tCardiovascular Diseases

\n\u2022\tReproductive Health

\n\u2022\tNeurodegenerative Health

\n\u2022\tRare Diseases

\n\u2022\tOthers

\nBy End-User-

\n\u2022\tHospitals and Diagnostic Laboratories

\n\u2022\tDTC Companies

\n\u2022\tGenetic Counselling Services

\n\u2022\tOther End-users

\nBy Region-

\nNorth America-

\n\u2022\tThe US

\n\u2022\tCanada

\n\u2022\tMexico

\nEurope-

\n\u2022\tGermany

\n\u2022\tThe UK

\n\u2022\tFrance

\n\u2022\tItaly

\n\u2022\tSpain

\n\u2022\tRest of Europe

\nAsia-Pacific-

\n\u2022\tChina

\n\u2022\tJapan

\n\u2022\tIndia

\n\u2022\tSouth Korea

\n\u2022\tSouth East Asia

\n\u2022\tRest of Asia Pacific

\nLatin America-

\n\u2022\tBrazil

\n\u2022\tArgentina

\n\u2022\tRest of Latin America

\n Middle East & Africa-

\n\u2022\tGCC Countries

\n\u2022\tSouth Africa

\n\u2022\tRest of the Middle East and Africa<\/p>\n

About Us:

\nInsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.<\/p>\n

Contact us:

\nInsightAce Analytic Pvt. Ltd.

\nVisit: www.insightaceanalytic.com

\nTel : +1 551 226 6109

\nAsia: +91 79 72967118

\ninfo@insightaceanalytic.com<\/p>\n

This release was published on openPR.
\n <\/p>\n","protected":false},"excerpt":{"rendered":"Genetic Screening Testing for Preventive Health Market InsightAce Analytic Pvt. Ltd. announces the release of a market assessment…\n","protected":false},"author":2,"featured_media":12030,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3846],"tags":[3369,267,3368,3364,3362,3367,3371,3370,3372,3361,3365,3363,3366,70,16,15],"class_list":{"0":"post-12029","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-genetics","8":"tag-advertising","9":"tag-genetics","10":"tag-marketing","11":"tag-media-release","12":"tag-news-release","13":"tag-pr","14":"tag-pr-marketing","15":"tag-pr-service","16":"tag-pr-strategy","17":"tag-presses-release","18":"tag-pressreleases","19":"tag-public-relations","20":"tag-publicity","21":"tag-science","22":"tag-uk","23":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/114321756168429766","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/12029","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=12029"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/12029\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/12030"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=12029"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=12029"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=12029"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}